---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-055156"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T19:01:29.007202+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences expands TYRA-300 into achondroplasia with positive preclinical data; TYRA-200 IND cleared

## Summary
- TYRA-300 increased body length by 17.6% in FGFR3 Y367C/+ mice (p<0.0001); femur +24.4%, tibia +38.3%, L4-L6 +23.9%.
- Company plans to submit IND for Phase 2 study in pediatric achondroplasia in 2024.
- FDA cleared IND for TYRA-200, an FGFR1/2/3 inhibitor; first patient dosing expected H2 2023.
- Compensation Committee adopted annual incentive plan; CEO target bonus 50% of base salary, other execs 40%.

## SEC filing metadata
- accession: 0001193125-23-055156
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312523055156/0001193125-23-055156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312523055156/d446194d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-055156
- JSON: https://secwatch.observer/filing/0001193125-23-055156.json
- Plain text: https://secwatch.observer/filing/0001193125-23-055156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.